Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
Nicolas J LlosaBrandon LuberAda J TamKellie N SmithNicholas SiegelAnas H AwanHongni FanTeniola OkeJiaJia ZhangJada DomingueElizabeth L EngleCharles A RobertsBjarne R BartlettLaveet K AulakhElizabeth D ThompsonJanis M TaubeJennifer N DurhamCynthia L SearsDung T LeLuis A DiazDrew M PardollHao WangRobert A AndersFranck HousseauPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The detection of a preexisting antitumor immune response in MMRp colorectal cancer (immunoreactive MMRp colorectal cancer) is not sufficient to predict a clinical benefit to T-cell checkpoint inhibitors. Intratumoral IL17-mediated signaling may preclude responses to immunotherapy. Drugs targeting the IL17 signaling pathway are available in clinic, and their combination with T-cell checkpoint inhibitors could improve colorectal cancer immunotherapy.See related commentary by Willis et al., p. 5185.